Erdafitinib dosing is indication-specific and must follow the applicable official prescribing information. The following information summarizes current U.S. BALVERSA labeling and is not an individualized prescription.
Current U.S. starting regimen
The current U.S. recommended starting dose is:
| Treatment stage | U.S. labeled regimen |
|---|---|
| Starting dose | 8 mg orally once daily |
| Tablet construction | Two 4 mg tablets |
| Possible increase | 9 mg once daily |
| Timing of increase | 14–21 days after starting |
| Main escalation consideration | Tolerability and serum phosphate |
| Treatment duration | Until disease progression or unacceptable toxicity |
The dose may be increased to 9 mg once daily at 14–21 days if the serum phosphate level is below 9.0 mg/dL and there are no ocular disorders or grade 2 or greater adverse reactions.
Phosphate monitoring
Serum phosphate should be assessed before treatment and monitored during therapy. The U.S. label recommends assessing phosphate at 14–21 days before considering the dose increase and then monitoring monthly for hyperphosphatemia.
Administration
BALVERSA is taken orally once daily, with or without food. Tablets should be swallowed whole.
Missed dose
A missed dose can be taken as soon as possible on the same day. The normal schedule should resume the next day. Extra tablets should not be taken to compensate.
Dose modification
Dose interruption or reduction can be required for adverse reactions, including ocular toxicity, hyperphosphatemia and other clinically significant toxicities.
Dose decisions should be based on the official label and clinical assessment rather than on a general website.
Renal impairment
The pharmacokinetic information in the original FDA assessment did not identify clinically meaningful trends with mild or moderate renal impairment, while pharmacokinetics in severe renal impairment or dialysis were not established in that assessment.
Hepatic impairment
Mild hepatic impairment did not produce clinically meaningful pharmacokinetic trends in the original FDA assessment. Pharmacokinetics in moderate or severe hepatic impairment were not established in that assessment.
Important product distinction
Erdanib is identified on this website in 4 mg and 5 mg strengths. Those stated Erdanib strengths should not be confused with the current U.S. BALVERSA dosing regimen or interpreted as evidence that a particular Erdanib tablet should be used to construct a prescribed dose.